XML 58 R44.htm IDEA: XBRL DOCUMENT v3.25.1
STOCKHOLDERS DEFICIENCY (Details Narrative) - USD ($)
 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Feb. 10, 2025
Dec. 13, 2024
Apr. 12, 2023
Jun. 20, 2024
Jan. 29, 2024
Oct. 20, 2023
Mar. 31, 2025
Mar. 31, 2024
Mar. 31, 2025
Mar. 31, 2024
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2021
Jan. 31, 2024
Cash fee, percentage             7.00%   7.00%            
Offering expenses $ 4,309,641                            
Stock-based compensation related to restricted stock units             $ 171,281 $ 185,019 $ 513,852 $ 555,057          
Number of outstanding shares of restricted stock units             279,700   279,700            
Unvested performance-based stock options granted estricted stock units                 274,549 59,842          
Restricted stock units number of shares outstanding granted                     184,443 152,432 40,707 22,343  
Withholding taxes related to restricted stock units, shares                 54,691            
Stock-based compensation to stock options             $ 176,410 205,176 $ 531,817 $ 615,716          
Unvested performance-based stock options granted                 418,945 88,911          
Number of shares outstanding granted                 0   264,945 238,838 60,566 95,167  
Withholding taxes related to restricted stock units, value                 $ 99,482            
Fees and expenses           $ 4,573,948     $ 9,224,056            
Exercise price per share           $ 2.12                 $ 5.46
Exercise price           $ 0.0001                  
Warrant issuance                 1,624,201            
Warrant issuance year five                 1,953,839            
Description of securities purchase agreement     The 2025 Sales Agreement and related prospectus is limited to sales of up to an aggregate maximum of $6.0 million of shares of the Company’s common stock. The Company pays A.G.P. 3.0% of the gross proceeds as a commission     an aggregate of (i) 1,325,000 shares of common stock (the “October 2023 Shares”), of the Company and (ii) pre-funded warrants (the “October 2023 Pre-Funded Warrants”) to purchase up to 1,033,491 shares of the Company’s common stock (the “October 2023 Pre-Funded Warrant Shares”). Pursuant to the October 2023 Purchase Agreement the Company also issued unregistered warrants (the “October 2023 Private Warrants”) to purchase up to 2,358,491 shares of the Company’s common stock (the “October 2023 Private Warrant Shares”) in a concurrent private placement (the “October 2023 Private Offering” and together with the October 2023 RD Offering, the “October 2023 Offering”). The October 2023 Shares and accompanying October 2023 Private Warrants were offered at a combined offering price of $2.12. The October 2023 Pre-Funded Warrants and accompanying October 2023 Private Warrants were offered at a combined offering price of $2.1199. The October 2023 Offering closed on October 24, 2023                  
Distributable value of dividend             $ 100   $ 100            
Purchase price per share $ 1.00                            
Common stock share purchased 4,688,000       1,831,503                    
Gross proceeds from Offering $ 4,687,786               $ 10,000,006            
Gross proceeds from exercise of Existing Warrants                 3,398,237 $ 103          
Net proceeds                 4,457,520 14,693,779          
Other related expenses             $ 0 $ 0 $ 0 $ 696,912          
Stock Warrants [Member]                              
Exercise price   $ 1.88   $ 1.88                      
Purchase of warrant of common stock series A   3,907,679   4,849,915                      
Warrants to purchase   1,953,839   3,233,277                      
Gross proceeds from exercise of Existing Warrants   $ 3,419,219   $ 6,078,561                      
Description of existing holder purchase of warrants   the Company agreed to adjust the exercise price of such portion of the December 2024 Existing Warrants to $0.875. Pursuant to the December 2024 Inducement Letter, the December 2024 Exercising Holder agreed to exercise, for cash, the December 2024 Existing Warrants to purchase an aggregate of 3,907,679 shares of common stock at the adjusted exercise price in exchange for the Company’s agreement to issue to the December 2024 Exercising Holder Series C common stock purchase warrants to purchase 3,907,679 shares of common stock (the “Series C Warrants”) and Series D common stock purchase warrants to purchase 1,953,839 shares of common stock (the “Series D Warrants” and together with the Series C Warrants, the “December 2024 Inducement Warrants,” and the shares issuable upon exercise of the December 2024 Inducement Warrants, the “December 2024 Inducement Warrant Shares”)   (i) lower the exercise price to $1.88 per share for the 3,233,277 June 2024 Existing Warrants being exercised pursuant to the June 2024 Inducement Letter and (ii) issue to the June 2024 Exercising Holder an aggregate of 4,849,915 warrants to purchase shares of common stock, comprised of Series A common stock purchase warrants to purchase 2,727,273 shares of common stock (the “June 2024 Series A Warrants”) and Series B common stock purchase warrants to purchase 2,122,642 (of which 1,624,201 shares of common stock are subject to stockholder approval) shares of common stock (the “June 2024 Series B Warrants” and together with the June 2024 Series A Warrants, the “June 2024 Inducement Warrants”). The Company received aggregate gross proceeds of $6,078,561 from the exercise of the June 2024 Existing Warrants by the June 2024 Exercising Holder (the “Warrant Inducement”)                      
Exercising holder released shares             1,443,277   1,443,277            
Private Placement [Member]                              
Exercise price per share $ 1.00                            
Common stock share purchased 4,688,000                            
Private Warrant Shares [Member]                              
Exercise price per share         $ 5.46                    
Common stock share purchased         1,831,503                    
2025 Sales Agreement [Member]                              
Common stock share purchased             413,400                
Net proceeds             $ 271,037                
Payment of commission fees             7,837                
Other related expenses             $ 164,054                
2024 Placement Agent Warrants                              
Shares of Common Stock                 91,575            
Exercise price             $ 6.825   $ 6.825            
Convertible Series A Preferred Stocks [Member]                              
Convertible preferred stock were outstanding             4,030   4,030            
Aggregate value                 $ 403,000            
Conversion price             $ 60.33   $ 60.33            
Convertible shares             $ 1.66   $ 1.66            
Distributable value of dividend             $ 100   $ 100            
Distributable value of dividend additional             $ 100   $ 100            
2023 Equity Distribution Agreement [Member]                              
Purchase of warrant shares             $ 50,000,000.0   $ 1,033,491